1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fibrotech Therapeutics Pty. Ltd. - Product Pipeline Review - 2013

Fibrotech Therapeutics Pty. Ltd. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Fibrotech Therapeutics Pty. Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Fibrotech Therapeutics Pty. Ltd. - Product Pipeline Review - 2013” provides data on the Fibrotech Therapeutics Pty. Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Fibrotech Therapeutics Pty. Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Fibrotech Therapeutics Pty. Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Fibrotech Therapeutics Pty. Ltd. - Brief Fibrotech Therapeutics Pty. Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Fibrotech Therapeutics Pty. Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Fibrotech Therapeutics Pty. Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Fibrotech Therapeutics Pty. Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Fibrotech Therapeutics Pty. Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Fibrotech Therapeutics Pty. Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Fibrotech Therapeutics Pty. Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Fibrotech Therapeutics Pty. Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Fibrotech Therapeutics Pty. Ltd. and identify potential opportunities in those areas.

Table Of Contents

Fibrotech Therapeutics Pty. Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Fibrotech Therapeutics Pty. Ltd. Snapshot 4
Fibrotech Therapeutics Pty. Ltd. Overview 4
Key Information 4
Key Facts 4
Fibrotech Therapeutics Pty. Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Fibrotech Therapeutics Pty. Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products Glance 9
Fibrotech Therapeutics Pty. Ltd. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Fibrotech Therapeutics Pty. Ltd. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Fibrotech Therapeutics Pty. Ltd. - Drug Profiles 12
FT-01 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
FT-011 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
FT-026 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
FT-061 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
FT-071 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Fibrotech Therapeutics Pty. Ltd. - Pipeline Analysis 17
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products by Therapeutic Class 17
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products By Target 18
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products by Route of Administration 19
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products By Mechanism of Action 20
Fibrotech Therapeutics Pty. Ltd. - Recent Pipeline Updates 21
Fibrotech Therapeutics Pty. Ltd. - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24



List of Tables

Fibrotech Therapeutics Pty. Ltd., Key Information 4
Fibrotech Therapeutics Pty. Ltd., Key Facts 4
Fibrotech Therapeutics Pty. Ltd. - Pipeline by Indication, 2013 6
Fibrotech Therapeutics Pty. Ltd. - Pipeline by Stage of Development, 2013 7
Fibrotech Therapeutics Pty. Ltd. - Monotherapy Products in Pipeline, 2013 8
Fibrotech Therapeutics Pty. Ltd. - Phase I, 2013 9
Fibrotech Therapeutics Pty. Ltd. - Preclinical, 2013 10
Fibrotech Therapeutics Pty. Ltd. - Discovery, 2013 11
Fibrotech Therapeutics Pty. Ltd. - Pipeline By Therapeutic Class, 2013 17
Fibrotech Therapeutics Pty. Ltd. - Pipeline By Target, 2013 18
Fibrotech Therapeutics Pty. Ltd. - Pipeline By Route of Administration, 2013 19
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products By Mechanism of Action, 2013 20
Fibrotech Therapeutics Pty. Ltd. - Recent Pipeline Updates, 2013 21
Fibrotech Therapeutics Pty. Ltd., Other Locations 22



List of Figures

Fibrotech Therapeutics Pty. Ltd. - Pipeline by Indication, 2013 6
Fibrotech Therapeutics Pty. Ltd. - Pipeline by Stage of Development, 2013 7
Fibrotech Therapeutics Pty. Ltd. - Monotherapy Products in Pipeline, 2013 8
Fibrotech Therapeutics Pty. Ltd. - Pipeline By Therapeutic Class, 2013 17
Fibrotech Therapeutics Pty. Ltd. - Pipeline Products By Mechanism of Action, 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.